Biomarkers - SMi's Third Summit: discovery, validation & qualification.
SMi's Third Summit on Biomarkers, held in London, included topics covering new technological and therapeutic developments in the field of biomarkers. This conference report highlights selected presentations on the development of biomarkers, novel biomarkers for cancer and other diseases, and safety issues relating to biomarkers.
French
Neil
N
University of Liverpool, MRC Centre for Drug Safety Science, Sherrington Buildings, Liverpool, UK. neil.french@liv.ac.uk
D000544:Alzheimer Disease / Q000134:cerebrospinal fluid / Q000175:diagnosis; D000818:Animals; D015415:Biomarkers / Q000032:analysis / Q000097:blood / Q000134:cerebrospinal fluid / Q000378:metabolism* / Q000652:urine; D054316:Biomarkers, Pharmacological / Q000032:analysis / Q000097:blood / Q000378:metabolism / Q000652:urine; D015197:Carcinogenicity Tests / Q000379:methods; D056486:Chemical and Drug Induced Liver Injury / Q000097:blood / Q000378:metabolism; D064420:Drug-Related Side Effects and Adverse Reactions / Q000097:blood / Q000378:metabolism / Q000652:urine; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced / Q000378:metabolism / Q000652:urine; D007878:Legislation as Topic; D008180:Lupus Erythematosus, Systemic / Q000378:metabolism; D008297:Male; D009369:Neoplasms / Q000175:diagnosis / Q000276:immunology / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000378:metabolism; D011786:Quality Control
D015415:Biomarkers; D054316:Biomarkers, Pharmacological